FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
8 letters match. Newest first.
-
DrugsWoodbine Products Company Inc.
Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
High risk -
DrugsIsland Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsHangzhou Yiqi Biotechnology Co., Ltd
FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.
High risk -
DevicesDiasol, Inc.
Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.
High risk -
DrugsBio-Medical Pharmaceutical Manufacturing Corporation
Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.
High risk -
DrugsSV Labs Corporation
SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.
High risk